Skin Cancer Clinical Trials & Research at Providence Medical Group
Skin cancer is the most common type of cancer worldwide, with basal cell
carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma being the
primary subtypes. While BCC and SCC are generally less aggressive and
highly treatable when detected early, melanoma is known for its potential
to metastasize and become life-threatening. The increasing incidence of
skin cancer underscores the urgent need for innovative treatments, making
clinical trials essential for advancing patient care.
Clinical trials for skin cancer are at the forefront of developing and
testing new therapies aimed at improving survival rates and quality of
life. These trials evaluate a wide array of treatment modalities, including
surgical techniques, radiation therapy, chemotherapy, targeted therapies,
and immunotherapies. Recent advancements in immunotherapy, particularly
immune checkpoint inhibitors, have revolutionized the treatment landscape
for melanoma, offering new hope for patients with advanced disease.
Providence Medical Group is currently enrolling patients for the following
skin cancer clinical trials:
No Clinical Trials